Phosphodiesterase-5 (PDE5) inhibitors are approved to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH) and pulmonary hypertension (PH). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.